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OBJECTIVES: The objective of this study was to assess
the compliance and treatment satisfaction with risperi-
done in a U.S. sample of patients with bipolar disorder.
METHODS: In June 2001, 573 persons reported being
diagnosed with bipolar disorder on a self-administered
questionnaire. Patients receiving risperidone were identi-
ﬁed and information on compliance and treatment satis-
faction was extracted. Satisfaction and compliance with
treatment were measured using the Drug Attitude 
Inventory (DAI) and a 5-point Likert scale. The satisfac-
tion scale ranges from not at all (1) to extremely satisﬁed
(5), while the DAI classiﬁes the patients in 3 groups, non-
compliant (-10 to 0), somewhat compliant (1 to 5), and
very compliant (6 to 10) with treatment. RESULTS:
Thirty-one (5.4%) of 573 patients with bipolar disorder
were receiving risperidone. The average length of treat-
ment was 33.1 (SD = 23.5) months. Twenty-three (73%)
of 31 patients reported being very or extremely (4 or 5)
satisﬁed with the medication, while only 4 patients (12%)
reported no or little satisfaction with treatment. The
majority of patients, 22 (68%), reported being very 
compliant with their treatment. CONCLUSION: In this
population of patients with bipolar disorder, patients
receiving risperidone appear to have a high satisfaction
with treatment and a high compliance rate.
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OBJECTIVE: Compliance plays a major role in chronic
conditions to help achieve a full course of therapy. All
chronic diseases have adherence to prescribed drug
therapy as obstacles to treatment. Potential consequences
of non-adherence include relapse, treatment resistance,
suicide, impairment of functioning (work, interpersonal)
and worsening of comorbid illnesses. All of these poten-
tial consequences can have a signiﬁcant economic burden
on the society. So we intended to evaluate the clinical efﬁ-
cacy of ﬂuoxetine 180mg (2 ¥ 90mg tablets) once a week
in ambulatory patients stabilized on Fluoxetine 40mg
daily. METHOD: Thirty patients stabilized on ﬂuoxetine
40mg daily were evaluated in a mirror image design.
They were switched to ﬂuoxetine 180mg (2 ¥ 90mg
tablets) once a week. Steady state serum drug concentra-
tion and Clinical Global Impression-Severity (CGI-S),
medication compliance and patient attitude survey were
obtained before and after the switch. RESULTS: Mean
age of the patients was 41.7 + 11.7 years, with 8 males
and all of them met DSM IV criteria for major depres-
sion. Mean duration of depression was 8 + 3 years. 
Fluoxetine/Norﬂuoxetine serum concentrations were 261
+ 185 and 295 + 206ng/ml (P = .21.). CGI-S was 2.5 +
0.7 and 2.6 + 0.7 before and after the switch. Compli-
ance before the switch was 73.6% before and 91% after
the switch. This difference was statistically signiﬁcant at 
p < 0.0001 (t = -7.8651, df = 29). 41% of the patients
strongly agreed that weekly dosing regimen was preferred
over daily regimen. CONCLUSION: Our evaluation 
indicates that once a week dosing is as equally clinically
efﬁcacious as a daily dose in the management of major
depression in our population of ambulatory patients. 
Signiﬁcant improvement in compliance can only have a
positive impact on the health outcome and costs.
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OBJECTIVES: To examine and describe gender differ-
ences in psychoactive medication treatment for AD/HD
in a population-based cohort. METHODS: Medical 
and school records of all children born (N = 5718) in
Rochester, MN 1976–1982 were reviewed to identify
those with AD/HD (N = 375). All psychoactive 
medications (psychostimulants [STIM], centrally acting 
alpha-adrenergic agonists [CAA] and/or tricyclic 
antidepressants [TCA]), doses prescribed, start and 
stop dates, and subtype of AD/HD clinical diagnosis 
were abstracted. Psychostimulant doses were converted 
to Methylphenidate Equivalent Units (MEU: 20mg
methylphenidate = 10mg dextroamphetamine = 10mg
amphetamine salts = 56.25mg pemoline). RESULTS:
Boys with AD/HD were more likely than girls to be
treated with STIM, either alone or in combination with
TCA and/or CAA (80.8% vs 69.1%, OR 1.9, 95% CI
1.1–3.2, p = 0.020). However, boys and girls were equally
likely to be treated with STIM alone (66.2% versus
63.8%, OR 1.1, 95% CI 0.7–1.8, p = 0.68). Mean age at
treatment onset was similar (boys 10.3 years, girls 10.7
years, p = 0.46). Median treatment duration was 34
months (mean = 42.0, SD = 37.1), with no gender differ-
ence. Median average daily dose of STIM was 21.3mg
MEU (mean = 24.4mg, SD = 11.0mg). Boys received 
signiﬁcantly higher average daily doses than girls (median
22.5 vs. 20.0mg MEU; p = 0.002). Treatment started 
signiﬁcantly earlier for combined (9.7 years) and 
hyperactive-impulsive subtypes (10.0 years) than for the
inattentive type (12.7 years). Treatment duration was 
signiﬁcantly longer for combined (40.5 months) than for
either hyperactive-impulsive (22.6 months) or inattentive
subtype (19.1 months). The gender differences in AD/HD
treatment described above could not be accounted for by
gender differences in AD/HD subtype. CONCLUSIONS:
Boys with AD/HD were more likely to be treated with
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psychostimulants, and received signiﬁcantly higher doses
of psychostimulants, suggesting disparities in AD/HD
treatment between boys and girls that may affect quality
of care.
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OBJECTIVES: Clinicians treating schizophrenia face
increasingly diverse populations, with different ethnic
groups having different medication adherence patterns.
The Texas Medicaid population with schizophrenia
includes large numbers of patients from several ethnic
groups, having broad use of the prevalent antipsychotic
medications within each ethnic group. The purpose of this
study was to assess the association between ethnicity and
adherence among Texas Medicaid clients with schizo-
phrenia, and to assess whether adherence within or across
ethnic groups differed depending on which antipsychotic
was used, after controlling for other factors. METHODS:
Texas Medicaid claims were retrieved for persons, age 21
to 65, diagnosed with schizophrenia or schizoaffective
disorder, initiating treatment with olanzapine (N = 1875),
risperidone (N = 982), or haloperidol (N = 726) between
1/1997 and 8/1998. For each of the three pairings of these
medications, the association between ethnicity (African
American, Mexican American, or Caucasian) or medica-
tion and days use of the medication in the year following
initiation was assessed using multivariate linear regres-
sion. Covariates included other patient demographics,
region, comorbid health conditions, and prior medication
and heath care resource use. RESULTS: Overall mean
adherence was 177 of 365 days (48.5%). African 
Americans and Mexican Americans were signiﬁcantly less
adherent than Caucasians in the haloperidol versus 
olanzapine and risperidone versus olanzapine compar-
isons (p < 0.05 for each comparison). For patients of all
ethnicities, olanzapine was associated with 19 more
adherent days than risperidone and 56 more adherent
days than haloperidol (p < 0.001 for each pairwise com-
parison). CONCLUSIONS: When other factors were 
controlled for 1) ethnicity was a signiﬁcant predictor of
adherence following initiation on an antipsychotic 
medication and 2) patients of all ethnicities were most
adherent when taking olanzapine, less adherent when
taking risperidone, and least adherent when taking
haloperidol.
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IMPROVING THE MEASUREMENT PROPERTIES
OF THE QUALITY OF LIFE IN DEPRESSION
SCALE
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OBJECTIVES: The Quality of life in Depression Scale
(QLDS) is the most widely used measure of quality of 
life (QoL) in clinical trials and studies of depression. 
The instrument has been validated in 18 languages. The
instrument, which adopts the needs model, is highly 
sensitive to changes in QoL and is well accepted by
respondents. Since its development new statistical models
have been introduced into instrument development. The
present study was designed to adapt the QLDS using item
response theory in order to improve its measurement
properties further. METHODS: Existing datasets were
subjected to Rasch analysis to identify misﬁtting items
and to look for gaps in the range of measurement. As
weaknesses were identiﬁed at the extremes (very good 
or very poor QoL) additional interviews were conducted
with patients scoring either high or low on the QLDS and
new qualitative analyses were made of the 40 original
interview transcripts. Potential new items were added to
the QLDS and poorly performing ones removed. This
version was administered to samples of depressed patients
in the UK, US, France and Germany. The data were again
subjected to Rasch analysis and a ﬁnal version identiﬁed.
Its psychometric properties were then assessed in a second
postal survey. RESULTS: A 30-item version was identi-
ﬁed with little item misﬁt or differential item functioning
in the different countries. This version had excellent 
psychometric properties including reproducibility and
construct validity. The main gain was an increase in the
measurement range from 2.5 to 4.3 logits, an increase of
72%. CONCLUSIONS: The measurement properties of
the QLDS have been improved, ensuring it provides valid
scores on a unidimensional QoL scale. The increased
measurement range makes the instrument more suitable
for use across the full range of depression severity and
hence more valid for use in antidepressant maintenance
studies.
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OBJECTIVE: An international literature review assessed
the epidemiology, treatment patterns and cost associated
